Amarin Plcuk's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Amarin Plcuk's ROA in the second quarter of 2026?
Amarin Corp Plcuk recorded a cumulative net loss of $-27 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -4.04%.

However, within the Healthcare sector 249 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 2986, from total ROA ranking in the first quarter of 2026 at 3523.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	-6.83 %	-1.51 %	-9.47 %	-0.56 %	-6.84 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-27	-34	-39	-86	-104
Return On Assets (TTM)	-4.04 %	-4.93 %	-5.66 %	-12.23 %	-14.68 %
AMRN's Total Ranking	# 2986	# 3523	# 3366	# 3448	# 3401
Total Assets (TTM) in million	624	646	754	660	670
Seq. Total Assets Change	-3.31 %	-14.34 %	14.26 %	-1.54 %	2.2 %
Seq. Net Income Change	-	-	-	-	-

AMRN's 5 Years Annual ROA >> Back to AMRN Management Effectiveness >> Compare AMRN ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 86
Sector	# 250
Overall	# 2902

Return On Assets Statistics
High	Average	Low
40.66 %	-27.09 %	-107.4 %
(Jun 30 2012)		(Mar 31 2012)

Financial Statements
Amarin Plcuk's Assets	$ 624 million	AMRN's Balance sheet
Amarin Plcuk's Income	$ -8 million	Quarterly AMRN's Income Statement
AMRN's Income by Division		See AMRN's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-9.47 %	-12.16 %	2.56 %	-28.04 %	18.17 %
Total Assets in million	754	833	948	924	1,285
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-39	-82	-59	-106	8
Annual Return On Assets	-5.15 %	-9.87 %	-6.23 %	-11.45 %	0.6 %

AMRN's 5 Years Annual ROA >> Back to AMRN Management Effectiveness >> Compare AMRN ROA to its Competitors

More Return On Assets Ratios
AMRN's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
AMRN's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for AMRN's Competitors
Subscribers only: Roa for Amarin Plcuk's Suppliers
Subscribers only: Return On Assets for AMRN's Customers

You may also want to know
AMRN's Roi	AMRN's Inventory Turnover Ratio	AMRN's Growth Rates	AMRN's Dividend Comparisons
	AMRN's Profitability Ratios	AMRN's Asset Turnover Ratio	AMRN's Dividend Growth
AMRN's Roe	AMRN's Valuation Ratios	AMRN's Financial Strength Ratios	AMRN's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-08T16:30:51+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.